ACE2 and COVID-19: As a farnesoid X receptor (FXR) inhibitor, UDCA has been shown to improve the prognosis of patients with COVID-19 by reducing the expression of angiotensin-converting enzyme 2 (ACE2), a viral host receptor, by inhibiting the FXR activity [12].